Summary The deuterated benzaldehyde derivative zilascorb(QH), 5,6-O-benzylidene-d-L-ascorbic acid, was administered once daily by i.v. injection in nude mice with grafted tumours of a human malignant melanoma (E.E.) and ovarian carcinoma (OVCAR-3) origins. Like benzaldehyde, zilascorb(2H) has been shown to induce protein synthesis inhibition at otherwise non-toxic doses in cells grown in vitro, and acts reversibly in the sense that protein synthesis returns to normal shortly after removal of the drug. The present data indicate that daily injections with zilascorb(2H) induce a tumour volume growth inhibitory effect in both tumour xenografts studied. Furthermore, from histological examinations of each single tumour it was found that tumours of drug-treated animals, although smaller than those of placebo-treated (i.e. control) animals, had, on average, a higher necrotic fraction than control tumours. Thus, it is concluded that zilascorb(2H) induces tumour necrotisation and not just inhibition of the rate of tumour cell production. Continued measurement of tumour volume after ended treatment with zilascorb(2H) indicated that surviving tumour cells resumed their normal growth rate immediately. The reversibility of the effect induced by this compound, earlier observed in vitro only, is therefore here confirmed to be valid also in two different tumour xenografts in vivo. The present data accords well with the assumption that protein synthesis inhibition is the primary cellular effect of zilascorb(2H) in vivo. We therefore conclude that zilascorb(2H)-induced cancer cell lethality in tumour xenografts probably comes as a secondary consequence of prolonged protein synthesis inhibition.
In many frequently occurring cancer types prognosis has not improved following chemotherapy in the way that many clinicians hoped for just two decades ago (Cairris, 1985; Corbett et al., 1987 (Strong, 1936; 1939, see Tisserand & Balacs, 1989 for a review). When several aldehydes were screened for antitumour effects in mice (Boyland, 1940) a few were shown to have significant antitumour effects at doses less than 20% of the LD50 dose. Later citral and citronellal (Osato, 1965) as well as derivatives of benzaldehyde (Kochi et al., 1980; 1985; 1988; Sakagami et al., 1991) have been tested in clinical studies which are of considerable interest although the design was not optimal. The lack of a control group makes it difficult to evaluate the cure rate, and the degree of effect is often weak and short-lasting and even lacking in many of the patients. However, some effects were found in most cancer types tested and no sideeffects were found in normal tissue. Thus, the effect of these compounds appears to have been, to a great extent, specific to cancer in the way such specificity was defined by Corbett et al. (1987) .
We have shown that the benzaldehyde derivatives act as reversible protein synthesis inhibitors (Pettersen et al., 1983a; 1983b; 1985) . This seems to be their primary cellular effect, and, thus, cell inactivation follows only as a result of protracted inhibition of protein accumulation. A problem concerning these drugs is, however, that their half-life in the organism is relatively short (Pettersen et al., 1986; Borretzen et al., 1989; Dornish et al., 1990 (Tanum et al., 1990 (Pettersen et al., 1991a; B0rretzen et al., 1989) . Furthermore, in the compound zilascorb(2H) (see Pettersen et al., 1991b) we used deuterated benzaldehyde to synthesise an ascorbate acetal having stronger effects in vitro than sodium benzylidene ascorbate (SBA) that was used by Kochi et al. (1988) . In the present study we (Rofstad et al., 1977) . The volume doubling time of this tumour was 4.4 days (Rofstad, 1984) . Tumour kinetic studies based on the method of 'per cent labelled mitoses' and DNA flow cytometry (Rofstad et al., 1980; Rofstad, 1984) have shown that the mean cell cycle time was 41 h while the tumour growth fraction was in the range from 76 to 97% and the tumour cell loss in the range from 33 to 52% (see Rofstad, 1984) . The NIH:OVCAR-3 cell line, established by Hamilton et al. (1983) Two to 4 representative sections were taken from each tumour and processed for light microscopy. The specimens were fixed in 5% buffered formalin, dehydrated and embedded in paraffin. Six to 8 glm thick sections cut from the paraffin blocks were stained with haematoxylin and eosin, and used for light microscopical evaluation. The microscopical appearance was compared with the observations made at the time of macroscopical examination and a semiquantitative evaluation of degree of tumour necrosis compared to vital tumour tissue was made.
Drugs Zilascorb(2H) was produced at Norsk Hydro's Research Center, Porsgrunn, Norway (B0rretzen et al., 1989) . The drug was injected as the sodium salt which is shown in Figure 1 .
Time after first injection (days) To extend the dose scale to higher doses we also present growth curves of a second experiment, including doses of 20 and 113 mg kg-' day-', in Figure 3 .
Tumour volume growth curves of an experiment on OVCAR-3 tumours including zilascorb(2H) doses of 20 and 40 mg kg-' day-' are shown in Figure 4 . Although tumour doubling times are longer for the OVCAR than for the E.E. tumours the drug effect seem to be similar.
During treatment animal body weight was measured for each animal once per week. In Table I (Table II) , while 1 mg kg-' gave no such response.
To shed light on the question of whether the reduced tumour volume growth rate is due to only growth inhibitory effects or to cell inactivation, we have performed a morphological examination of all tumours after the treatment period. All animals were sacrificed the day after the last treatment and a macroscopic as well as a microscopic examination were done. The morphological appearances of Time after first injection (days) Figure 3 A similar experiment to that described in the legend to Figure 2 , only with different drug doses. A: 20 mg kg-') than for the placebo-treated animals. Thus, the drug-induced growth-inhibition demonstrated in Figure 2 is due, mainly, to tumour cell inactivation and degeneration. Since the protein synthesis inhibition induced by zilascorb(2H) was reversible in the in vitro cell system (Pettersen et al., 1991b) it was important to see whether this was also the case in the in vivo system. We therefore allowed the tumours of the 20 mg kg-' group shown in Figure 3 to continue growth after the end of the treatment. If the drug acts in a truly reversible manner we would expect the tumour to resume growth after treatment at the same rate as those treated with placebo.
In Figure 9 the complete tumour volume growth curve is shown together with that of the control. From these data, the tumours quickly resume growth at a rate similar to that of the placebo-treated tumours as soon as drug treatment stops.
Discussion
The main finding of the present paper is that protracted treatment with zilascorb(2H) induces an antitumour effect in Figure 9 Tumour volume growth curves of E.E. melanoma tumour xenografts during and after daily treatment with 20 mg kg-' zilascorb(2H).
two different human tumour xenografts. On basis of our morphological studies of tumour necrosis, as indicated in Table III and Figures 5 to 8 , we conclude that zilascorb(2H) treated tumours are more necrotic than placebo treated tumours. We acknowledge the problem that our measurement of the fraction of the tumour that is necrotic involves elements of subjectivity and that our method do not extend to the production of a stereological picture of the tumour. However, taking into account the fact that the zilascorb(2H) treated tumours have a much smaller volume than the placebo treated tumours at the time of fixation we believe this conclusion to be sound. Thus, the growth inhibition demonstrated by the tumour volume growth curves of Figures 2, 3 and 4 to some extent underestimates the cellular effect of the drug. Included in the volume of the zilascorb(2H) treated tumours are drug-induced necrotic material that has not, at the time of tumour fixation, been removed by the vascular system of the tumour.
Comparing the effect of zilascorb(2H) here observed with that observed by others using other benzaldehyde derivatives in tumour bearing mice (Takeuchi et al., 1978; Taetle & Howell, 1983) it seems that zilascorb(2H) is more effective. In fact, experiments using various benzaldehyde derivatives against tumours grown in mice have often shown little or no effect, although the same derivatives were reported to be effective in patients (Kochi et al., 1980; 1985; 1988; Tatsemura, 1990) . One can wonder whether this seeming difference between the effect as seen in mice and in humans could be due to some metabolic difference between the two species, or perhaps, to differences in administration of the drug, being i.v. injections in humans and i.p. injections in the referred experiments in mice. Recently it has, however, been shown that benzaldehyde, after i.p. administration as dissolved in fatty acids in mice inoculated with P388 leukaemia cells, increased the animals life span with 50-100% (Balazova & Koza, 1988) , indicating that the duration of the drug availability in the tumour is an important parameter (B0rretzen et al., 1989) .
Primary protein synthesis inhibition as a possible cause of the antitumour effect Zilascorb(2H) acts as a reversible protein synthesis inhibitor in cultured cells (Pettersen et al., 1991b) . While protein syn-thesis was reduced immediately on addition of zilascorb(2H) to the culture medium, cell inactivation appeared only after extended treatment, and only at drug doses giving rise to considerable reduction in the rate of protein accumulation. The reversibility was most clearly demonstrated by our finding that the few cells (0.7%) surviving a short treatment of 10 h with a gigant dose of 10 mM zilascorb(2H), regained completely normal growth rate immediately after ended treatment (Pettersen et al., 1991b) . Our in vitro studies, therefore, point to protein synthesis inhibition as the cause of cell death from zilascorb(2H). The antitumour effect appeared only after more than 4 days of treatment (Figures 2, 3 and 4) . This is easily explained if one takes into consideration that a mild protein synthesis inhibition might need to be imposed on the cells for several days before the lack of vital proteins become life threatening.
Zilascorb(2H) appears to have an unusual dose response (Figures 2 and 3) . While 1 mg kg-' day-' is obviously too low a dose to result in a tumour effect in the E.E. malignant melanoma xenograft, 5 mg kg-' day-' is high enough, and higher doses do not seem to increase the response. Although this finding is unusual as compared to most other drugs tested for an antitumour effect, it is very much in line with our findings concerning the protein synthesis inhibition induced by zilascorb(2H) in cell cultures (Pettersen et al., 1991b) . In those cells, the rate of protein synthesis was reduced to about 35% of its normal level at a drug concentration of 1 mM, and could not be reduced much by a further increase in drug concentration. Furthermore, from the data of Figure 9 , the antitumour effect of zilascorb(2H) is demonstrated to be just as reversible as the protein synthesis inhibition induced in vitro (Pettersen et al., 1991b) . Thus, this accordance between protein synthesis inhibition in vitro and tumour volume growth delay in vivo concerning both dose response and reversibility indicate that inhibition of protein synthesis is also in vivo the primary cellular effect of zilascorb(2H).
Lack of side effects
In the present experiments, no signs of any side-effects were seen in the animals, there was not observed any difference in body weight between drug treated and placebo treated animals (Table I) We know that the drugs tested in clinical studies by Dr Kochi (1980 Kochi ( , 1985 Kochi ( , 1988 , and later by others (Tatsemura et al., 1990) , induced some anticancer effect without any observed side-effects and this is given an explanation with the present hypothesis. Warrington (1986) suggested that normal cells, as a response to protein synthesis inhibition, will stop cycling while cancer cells will not. In our opinion it is more likely that the organism responds to reduced protein synthesis by enforcing growth-stimulatory signals on the normal stem cells making sure that the needs for necessary proteins and new cells are satisfied. As far as we know there is no indication that cancer cells have any special ability to continue growth in presence of a protein synthesis inhibitor. Our view on this point is strongly supported by our own earlier studies concerning the relation between cell cycling and protein accumulation of cancer cells in vitro. Using either cycloheximide (R0nning et al., 1981) or benzaldehyde (Pettersen et al., 1983a,b) to induce a reversible protein synthesis inhibition, we found that a time-limited protein synthesis inhibition slowed down the rate of cell-cycle progression in all stages of interphase. Furthermore, in the absence of protein accumulation, cell division did not take place (R0nning et al., 1981) although there was still some cell-cycle progression (R0nning & Lindmo, 1983; R0nning & Pettersen, 1984) .
The present hypothesis presents a possibility to develop new, cancer-specific chemical agents. However, it is little known about the degree of effect on the tumour that may come out of such a treatment. Basically we have no guarantee that a chemically induced effect in a tumour, although specific to the tumour, would be very strong, or even involve inactivation of cancer cells. However, even a growth inhibition, if it is induced in the tumour only, may give a significant contribution in the treatment of many cancer patients. The present treatment, although not able to remove all cancer cells in any of the treated animals over an 18 or 24 days period, seems to have inactivated, and not just inhibited, cancer cells.
